Cellbyte
Category: AI in Healthcare
AI-native platform accelerating pharmaceutical drug launches through automated data analysis and insights Cellbyte was founded in 2024. The company is led by Felix Steinbrenner. Based in Munich, Germany. Team size: 11-50. Total funding raised: $2.75 million. Latest round: Seed. Key investors include Frontline Ventures, Y Combinator, Pace Ventures, Saras Capital, Springboard Health Angels.
- Founded
- 2024
- Headquarters
- Munich, Germany
- Team size
- 11-50
- Total funding
- $2.75 million
Value proposition
Reduces drug launch timelines by 50% via AI-driven automation, real-time data analysis, and workflow optimization
Products and solutions
AI copilots for P&MA teams, Real-time clinical, pricing, and regulatory data analysis tools, Natural language query interface for complex data insights, Drug Explorer for global regulatory and pricing data, Document Intelligence for multilingual document analysis, Agentic Workflows for automated processes, Data Vault for secure internal data upload, benchmarking, and team sharing
Unique value
Specialized AI models trained on pharmaceutical domain data, combining clinical, pricing, and regulatory workflows with real-time processing capabilities
Target customer
Pharmaceutical companies (specifically Pricing & Market Access teams) and global drug launch stakeholders
Industries served
Pharmaceuticals, Healthcare technology, Life sciences
Technology advantage
Processes millions of data points in real-time, automating tasks like HTA strategy design, pricing corridors, and payer negotiations
How they differentiate
Cellbyte integrates clinical, pricing, regulatory, and Health Technology Assessment (HTA) data into a unified AI platform, offering real-time insights and automation for drug launch workflows. Unlike competitors, it focuses on continuous market tracking and natural language query capabilities for pricing strategy
Main competitors
Legacy pharmaceutical databases and consulting firms, Traditional market access tools
Key partnerships
Frontline Ventures (lead seed investor), Y Combinator (accelerator), Bayer (pharma client), Springboard Health Angels, Pace Ventures, Saras Capital
Notable customers
Bayer, Additional Top-20 pharmaceutical companies (unnamed publicly)
Major milestones
Secured $2.75M seed funding in November 2025 (Frontline Ventures lead), Onboarded major pharmaceutical clients including Bayer within weeks of launch, Reached Top-20 pharma customers by end of 2025, Expanded into key global markets (U.S., Europe); SF presence listed alongside Munich HQ, Reached six-figure ARR; team scaled from 3 to ~13 by mid-2026
Growth metrics
Six-figure ARR within weeks of launch; grew from 3 founders to 9 by end-2025 and ~11–13 by mid-2026; Top-20 pharma customers onboarded; hiring to scale GTM (Founding AE, GM Life Sciences)
Market positioning
Positioned as an AI-native platform accelerating pharmaceutical drug launches through automated data synthesis and market intelligence, targeting global pharmaceutical companies seeking to reduce time-to-market
Geographic focus
Primarily focused on major pharmaceutical markets including the U.S., Germany, France, and the U.K., with plans for international expansion
Patents and IP
No public patents mentioned; focus on proprietary AI models and workflows
About Felix Steinbrenner
Second-time founder and Y Combinator alumnus with prior success selling $3M+ ACV enterprise deals to customers like H&M through a previous YC startup. Combines entrepreneurial experience with AI application expertise in healthcare.
More AI in Healthcare companies
Official website: https://www.cellbyte.com/